NASH

Explore the complexities of NASH research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against NASH with flcube.com.

NMPA Approves New Indication for J&J's Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line
CompanyDrug

NMPA Approves New Indication for J&J’s Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line

Johnson & Johnson (J&J) (NYSE: JNJ) announced that China's National Medical Products Administration (NMPA) has approved a new indication for Tecvayli (teclistamab injection) for adult patients with relapsed or refractory…

Enhertu Approved in China as First Tumor-Agnostic HER2-Targeted Therapy – Daiichi Sankyo's ADC Wins Conditional Approval for HER2-Expressing Solid Tumors

Enhertu Approved in China as First Tumor-Agnostic HER2-Targeted Therapy – Daiichi Sankyo’s ADC Wins Conditional Approval for HER2-Expressing Solid Tumors

Yifan Pharmaceutical Signs Exclusive Commercialization Agreement With Eisai for Halaven in Mainland China – Originator Anti-Tumor Drug Strengthens Oncology Portfolio

Yifan Pharmaceutical Signs Exclusive Commercialization Agreement With Eisai for Halaven in Mainland China – Originator Anti-Tumor Drug Strengthens Oncology Portfolio

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Guangdong Zhongsheng Pharma Initiates Phase IIb Study for ZSP1601 in NASH

CompanyDrug

HighTide Therapeutics’ HTD1801 Meets Primary and Secondary Endpoints in Type 2 Diabetes Phase II Study

CompanyDeals

Medisan Pharmaceutical Secures PPAR Agonist Technology from China Pharmaceutical University

CompanyR&D

Diapin Therapeutics Announces Breakthrough Preclinical Results for DT-109 in NASH Treatment

CompanyDrug

Inventiva and Chia Tai Tianqing’s Lanifibranor Advances with CDE Filing

CompanyDrug

Inventiva and Chia Tai Tianqing File Clinical Trial for Lanifibranor with CDE

CompanyDrug

Eli Lilly’s Tirzepatide Achieves Primary Endpoints in Chinese Obesity Study

CompanyDrug

Sciwind Biosciences Initiates Phase III Trial for Ecnoglutide in Type 2 Diabetes

Show More